Overview
Not all patients metabolize medications the same way. Genetic variations in drug-metabolizing enzymes can cause the same medication to be highly effective in one patient — and ineffective or even harmful in another.
Pharmacogenomics (PGx) testing from Chemisys Laboratories gives providers a genetic roadmap for medication selection and dosing — reducing trial-and-error prescribing and improving patient outcomes.
Testing is done once — results guide prescribing decisions for a lifetime.
Why it matters
Clinical value
Enzyme profiling
CYP2D6, CYP2C19, CYP2C9, CYP3A4/5 enzyme profiles and metabolism categories (poor, intermediate, normal, rapid, ultra-rapid).
Reduce adverse reactions
Improve medication efficacy and minimize polypharmacy risks.
Clinical guidance
Guide antidepressant and antipsychotic selection, support opioid prescribing in pain management, inform addiction treatment medication choices.
One-time testing
Results guide prescribing decisions for a patient's lifetime.
What's included
Capabilities
- CYP2D6, CYP2C19, CYP2C9, CYP3A4/5 enzyme profiles
- Metabolism categories: poor, intermediate, normal, rapid, ultra-rapid
- Drug-gene interactions relevant to current medications
- Actionable guidance for dosing adjustments or alternative drug selections
- Supports antidepressant, antipsychotic, opioid, and addiction-treatment decisions
Related services
Explore more
NGS
Deep genetic insight powered by next-generation sequencing — from oncology profiling to infectious disease.
Learn moreAddiction Treatment
Comprehensive toxicology solutions designed specifically for MAT, IOP, residential, sober living, and telehealth programs.
Learn morePain Management
Comprehensive toxicology panels that help providers verify adherence, detect diversion, and protect prescribing decisions.
Learn more